Aggregated price index with volume information
Summary:
- Biotechnology stocks down 0.4% on average while median return down 0.4% in a day
- Biotechnology stocks down 1.7% on average while median return down 1.0% in a week
- Biotechnology stocks down 11.5% on average while median return down 11.4% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $APLT 85.8%, $IMVT 71.9%, $CLRB 46.7%, $IMNM 33.2%, $DERM 31.7%
- 1M losers are : Losers for past month are $NGM -47.5%, $CAPR -48.4%, $PSTV -52.5%, $MORF -58.9%, $BCLI -88.6%
- 1W winners are : Winners for past week are $IMVT 88.3%, $LIXT 31.7%, $PSTX 25.3%, $BIVI 20.9%, $CASI 20.0%
- 1W losers are : Losers for past week are $SGMO -22.3%, $EDSA -25.9%, $MORF -37.5%, $CAPR -37.8%, $BCLI -78.7%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 5.9%, for the past 3 months is 7.0%
In the past month for a 5 days rolling window, the highest corrrelation is 16.9%, the lowest correlation is -0.4%, the latest correlation is -0.4%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 56.1% between ABIO and AMGN
The lowest correlation is -66.5% between ALEC and APRE
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Monday, October 2, 2023 at 8:00 a.m. ET.
TAMPA, Fla., September 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts.
WILMINGTON, Del., September 29, 2023--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream$4.1M revenues in fiscal year 2023, representing a 280% increase over the previous fiscal year and $2.3M revenues in fiscal Q4 2023, representing 123% increase quarter over quarter ("QoQ")Strengthens pharmaceutical pipeline with launch of INM-900 series program targeting neurodegenerative diseases such as Alzheimer's Vancouver, British Columbia--(Newsfile Corp. - September 29, 2023) - InMed Pharmaceut
Unraveling the Factors That Could Limit OPKO Health Inc's Outperformance
Unpacking the Risks and Rewards of Investing in Illumina (ILMN)
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.
The iconic money manager has struggled the last two months. Let's see what she's buying to get back on track.
The consensus price target hints at a 73.9% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.